One of Canada’s largest licensed weed producers has formed a strategic partnership with a major pharmaceutical company, marking the first — and much anticipated — foray of Big Pharma into the legal cannabis industry.

Tilray, which is largely a British Columbia-based company but with headquarters in Toronto, announced early Monday morning that it had signed a binding letter of intent with Sandoz Canada, an affiliate of Sandoz International GmBh, which is part of the Swiss pharma giant Novartis AG.

Read more at Vice Money